Lilly Sees Positive Results With Next-Gen Alzheimer’s Drug Donanemab
Patients Saw Less Cognitive, Functional Decline In Phase II Trial
Lilly reported positive results from a Phase II pivotal trial of donanemab, which targets a modified form of beta-amyloid called N3pG, and has a second pivotal Phase II study under way.
You may also be interested in...
Aduhelm commercialization was a bust, so Biogen’s next big hope for a potential blockbuster Alzheimer’s therapy is partner Eisai’s amyloid protofibril-targeting antibody lecanemab.
The Center for Medicare and Medicaid Services’ final decision on Medicare coverage favors anti-amyloid antibodies approved for Alzheimer’s disease based on efficacy rather than biomarker data.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.